newsfilter
← Latest News
PR Newswire·

Seelos Therapeutics Doses First Patient in a Registrational Phase II/III study of SLS-005 in Spinocerebellar Ataxia

Seelos will also present at the International Congress for Ataxia Research in November NEW YORK, Oct. 25, 2022 /PRNewswire/ -- Seelos Therapeutics, Inc. (NASDAQ:SEEL), a clinical-stage biopharmaceutical company focused